Bexagliflozin was noninferior compared with the control group in terms of MACEs and hospitalizations for HF.38 More studies are needed to investigate whether bexagliflozin has a similar cardioprotective profile to the other commonly prescribed SGLT-2 inhibitors, which play a well-recognized role in reducing MACEs and hospitalization rates. The gene discussed is SLC5A2; the disease is hydrops fetalis.